Anticancer phototherapy using activation of E-combretastatins by two-photon–induced isomerization
Hadfield, JA, Bisby, RH, Scherer, KM, Botchway, SW and Parker, AW 2014, 'Anticancer phototherapy using activation of E-combretastatins by two-photon–induced isomerization' , Journal of Biomedical Optics, 20 (5) , pp. 1004-1.
- Accepted Version
Download (760kB) | Preview
The photoisomerization of relatively nontoxic E-combretastatins to clinically active Z-isomers is shown to occur in solution through both one- and two-photon excitations at 340 and 625 nm, respectively. The photoisomerization is also demonstrated to induce mammalian cell death by a two-photon absorption process at 625 nm. Unlike conventional photodynamic therapy (PDT), the mechanism of photoisomerization is oxygen- independent and active in hypoxic environments such as in tumors. The use of red or near-infrared (NIR) light for two-photon excitation allows greater tissue penetration than conventional UV one-photon excitation. The results provide a baseline for the development of a novel phototherapy that overcomes nondiscriminative systemic toxicity of Z-combretastatins and the limitations of PDT drugs that require the presence of oxygen to promote their activity, with the added benefits of two-photon red or NIR excitation for deeper tissue penetration.
|Themes:||Health and Wellbeing|
|Schools:||Schools > School of Environment and Life Sciences > Biomedical Research Centre|
|Journal or Publication Title:||Journal of Biomedical Optics|
|Publisher:||Society of Photo-optical Instrumentation Engineers (SPIE)|
|Depositing User:||JA Hadfield|
|Date Deposited:||31 Oct 2014 16:57|
|Last Modified:||22 Jan 2015 17:39|
Actions (login required)
|Edit record (repository staff only)|